Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602198 · ClinicalTrials.gov registry record · NA
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
A NA study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01602198 is a NA study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 1 participants.
The verdict
NCT01602198, a NA study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.
Interventions
- DRUG Placebo transdermal patch
- DRUG Exelon [rivastigmine] transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602198
The ClinicalTrials.gov registry entry for NCT01602198 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo transdermal patch is the first listed.
NCT01602198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602198 about?
NCT01602198 is a clinical study titled "Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients". The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.
What is the current status of trial NCT01602198?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2011-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01602198?
The interventions under investigation include: Placebo transdermal patch (DRUG), Exelon [rivastigmine] transdermal patch (DRUG).
Who is sponsoring clinical trial NCT01602198?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.